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To evaluate the potential inhibitory eect of theophylline on the pulmonary oxidative stress in asthma and chronic
obstructive pulmonary disease (COPD), we concomitantly measured the blood levels of theophylline, a non-
selective phosphodiesterase (PDE) inhibitor and lipid peroxides as an index of oxidative stress. The plasma levels of
lipid peroxides were significantly elevated in patients with asthma (348+011 nmol ml71; mean+SEM; n=21,
P5001), non- or ex-smoking patients with COPD (355+011 nmol ml71; n=20, P5001), and current-smoking
patients with COPD (353+015 nmol ml71; n=15, P5001), respectively, as compared to those of non-smoking
controls (302+008 nmol ml71; n=19). There was a significant negative correlation between the plasma level of
lipid peroxides and the forced expiratory volume in 1 sec (FEV1)% of forced vital capacity in these subjects
(r=70304; n=75, P5001). In asthmatics, there was a significant negative correlation between the plasma level of
lipid peroxides and the serum level of theophylline (r=70495; n=18, P5005). These results suggest that there
may be increased oxidative stress in patients with asthma and COPD, and indicate that oxidative stress could
possibly attribute to the pathophysiology of asthma and COPD in leading to airflow obstruction and that
theophylline could potentially inhibit oxidative stress in the process of bronchopulmonary inflammation in
asthmatics.
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Airway inflammation as assessed by endobronchial biopsy
and bronchoalveolar lavage appears to play a central
pathophysiological role in patients with asthma and chronic
obstructive pulmonary disease (COPD) (1–3). Non-invasive
measurement of biochemical markers of airway inflamma-
tion might be valuable and useful tools for the assessment
and management of patients with pulmonary diseases.
Increased exhalation of hydrogen peroxide (H2O2) in
patients with adult respiratory distress syndrome (ARDS),
asthma, and COPD has been shown to be associated with
an increased oxidative stress in the airways (4–6). In these
patients the plasma level of lipid peroxides has been
observed to be a useful marker for assessment of oxidative
stress (7).Received 2 September 1999 and accepted in revised form 4 January
2000
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species in oxygen-dependent bactericidal processes has been
established by Babior (8). Despite their protective function,
there has been a major interest in their role in the
pathogenesis of a variety of destructive tissue damage.
Singlet oxygen and hydroxyl radicals derived from super-
oxide anions are extremely reactive in their breaking DNA
strains, altering of enzyme activities, and initiation of lipid
peroxidation (9). Enhanced generation of oxygen radicals
would be expected to be accompanied by elevated levels of
oxidation products such as lipid peroxides.
Theophylline, a non-selective phosphodiesterase (PDE)
inhibitor, is used for the treatment of asthma and COPD.
The therapeutic eectiveness of theophylline has been
mainly focused on its ability to produce bronchodilation.
However, recent reports support the possibility that
theophylline has immunomodulatory and anti-inflamma-
tory activities which result from inhibition of inflammatory
cell activation (10–12).
With respect to pulmonary oxidative stress and lung
function, the actions of theophylline remain to be clarified.
We have, therefore, measured and compared the pulmon-
ary function and the blood levels of lipid peroxides and
theophylline in patients with asthma and COPD.# 2000 HARCOURT PUBLISHERS LTD
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SUBJECTS
Four groups of subjects were studied: healthy non-smoking
control subjects (group A) (n=19; mean +SEM age,
529+31 years), non- or ex-smoking patients with asthma
(group B) (n=21; 662+31), non- or ex-smoking patients
with COPD (group C) (n=20; 735+11), and current-
smoking patients with COPD (group D) (n=15; 735+23).
Except for the patients of group D, subjects in the other
three groups were not current smokers and were classified
as non-smokers or ex-smokers (discontinuation of smoking
for at least 3 months) based on medical history. Exclusion
criteria for controls were current or previous pulmonary
disorders possibly contributing to chronic airflow obstruc-
tion (e.g., tuberculosis, sarcoidosis, and bronchiectasis),
regular intake of vitamin C and E, and treatment with
inhaled N-acetylcysteine. Patients in the three groups B, C,
and D did not take regular intake of vitamin C and E, or
treatment with inhaled N-acetylcysteine. The diagnosis of
asthma and COPD was made by a respiratory physician on
the basis of laboratory findings and medical history
according to the diagnostic criteria of American Thoracic
Society (13,14).
Asthma patients were further classified as atopic or non-
atopic based on immunological findings and medical
history. Severity of asthma were classified as steps 1–4
according to Global Initiative for Asthma (13), and severity
of COPD as I–V according to the Hugh-Johnes classifica-
tion for dyspnoea, respectively. The medication consisted of
inhaled or oral 2-agonists, inhaled or oral corticosteroids,
inhaled ipratropium bromide, anti-allergic drugs, and/or
oral theophylline. The condition of patients with asthma
and COPD was stable with no increase in symptoms or
exacerbation in the previous month. Informed consent was
obtained from all subjects.
MEASUREMENT OF LIPID PEROXIDES,
THEOPHYLLINE, AND PULMONARY
FUNCTION
Pulmonary function was measured with routine spirometry
(Chestac-33; Chest Co. Ltd., Tokyo, Japan) in all subjects,
and venous blood was withdrawn at the respiratory
outpatient clinic. Lipid peroxides in the plasma were
measured spectrophotometrically as thiobarbituric acid
(TBA) and malondialdehyde (MDA) adducts according to
Yagi (15). Theophylline in the serum was measured by
cloned enzyme donor immunoassay according to Hender-
son et al. (16).
STATISTICAL ANALYSIS
All values were expressed as mean+SEM. Statistical
significance of dierence in variance between independent
groups was assessed with the F-test. Unpaired Student’s t-
test (two-tailed) was used to test the significance of
dierences between means of the two independent groupsif equal variance was found between the two groups;
otherwise the Mann–Whitney U-test (two-tailed) was
employed. P-values of less than 005 were considered
significant.
Results
LIPID PEROXIDES, THEOPHYLLINE, AND
PULMONARY FUNCTION
The characteristics among the four groups are shown in
Table 1. While there were significant dierences in age
among the four groups, lipid peroxides levels were not
aected by age in all the 75 subjects (Fig. 1).
The plasma levels of lipid peroxides were significantly
elevated in groups B, C and D (348+011 nmol ml71,
n=21, P5001; 355+011 nmol ml71, n=20, P5001;
353+015 nmol ml71, n=15, P5001; respectively) as
compared with those of group A (302+008 nmol ml71,
n=19) (Fig. 2).
A significant negative correlation between the plasma
level of lipid peroxides and FEV1 % of forced vital capacity
in all subjects of these four groups (r=70304; n=75,
P5001) (Fig. 3).
There was a significant negative correlation between the
blood levels of lipid peroxides and theophylline in patients
with asthma (r=70495; n=18, P5005) (Fig. 4), but this
correlation was not observed in patients with COPD.
There were no significant dierences in the plasma levels of
lipid peroxides among subjects treated with or without
theophylline in patients of the three groups B, C and D
(P=0442; with theophylline: 354+007 nmol ml71,
n=45; without theophylline: 341+018 nmol ml71,
n=11, respectively).
There were no significant dierences in the plasma levels
of lipid peroxides among subjects treated with or without
steroids in patients of the three groups B, C and D
(p=0508; with steroids: 345+010 nmol ml71, n=20;
without steroids: 355+009 nmol ml71, n=36, respec-
tively).
The guidelines of the Ministry of Health and Welfare in
Japan for asthma management and prevention in 1998
recommends the use of appropriately-dosed inhaled beclo-
metasone dipropionate even in mild asthmatics in step 1.
Out of 11 asthmatics treated with steroids 200–600 g
day71 of beclometasone dipropionate were administered by
inhalation in four, 125–5 mg day71 of prednisolone orally
in seven and 125 mg day71 of prednisolone orally in one.
Out of four non-currently smoking COPD patients treated
with steroids 300–400 g day71 of beclometasone dipro-
pionate were administered by inhalation in two and 25–75
mg day71 of prednisolone orally in three. Out of five
current smoking COPD patients treated with steroids 300–
600 g day71 of beclometasone dipropionate were admi-
nistered by inhalation in two and 25–5 mg day71 of
prednisolone orally in four. While it is dicult to compare
the actual doses of steroid administered between by
inhalation and/or orally, there was no significant correla-
tion between the blood levels of lipid peroxides and doses of
TABLE 1. Characteristics among the four groups
Control Bronchial asthma Non- or ex-smoking
COPD
Currently smoking
COPD
Group A B C D
n 19 21 20 15
Male/female 8/11 12/9 18/2 12/3
Age 529+31 662+31** 735+11** 735+23**
Atopic/non-atopic 9/12
Step(1/2/3/4) 12/7/2/0
Hugh-Johnes (I/II/III/IV/V) (1/3/13/3/0 0/5/8/0/0
Smoking(non-/ex-/current-) 19/0/0 12/9/0 2/18/0 0/0/15
Dose of theophylline day71 3389+282 (n=18) 3647+170 (n=17) 3700+367 (n=10)
Theophylline serum level (mg ml71) 766+093 (n=18) 1076+122(n=17) 782+081 (n=10)
Medicated with/without
Steroid 11/10 4/16 5/10
2-agonists 7/14 5/15 10/5
Ipratropium bromide 0/21 8/12 5/10
Anti-allergic drugs 8/1 30/20 3/12
Forced vital capacity (FVC) (l) 299+025 263+020 236+015* 241+019
%FVC 980+38 955+517 97+51** 828+53*
Forced expiratory volume
in 1 sec (FEV1) (l)
265+024 179+014** 108+010** 130+011**
FEV1% 886+19 710+30** 493+27** 552+34**
Values are expressed as mean+SEM. *P5005, **P5001 compared to the control.
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(P=0391, r=0146) assuming that 600 g day71 of
beclometasone dipropionate administered by inhalation is
equal to 5 mg day71 of prednisolone orally.FIG. 1. There is no significant correlation between the
plasma level of lipid peroxides and ages among the four
groups (* group A, control; * group B, patients with
asthma; ~ group C, non- or ex-smoking patients with
COPD; & group D, currently smoking patients with
COPD).Discussion
In this study a significant elevation in the plasma level of
lipid peroxides was observed in patients with asthma and
COPD. Interestingly there was a significant negative
correlation between the plasma level of lipid peroxides
and FEV1 % of forced vital capacity in all subjects. These
results suggest that there may be increased oxidative stressFIG. 2. The plasma level of lipid peroxides among the four
groups (group A, control; group B, patients with asthma;
group C, non- or ex-smoking patients with COPD; group
D, currently smoking patients with COPD). Values are
means+SEM. **P5001 compared to the control.
FIG. 3. The correlation between the plasma level of lipid
peroxides and the forced expiratory volume in 1 sec
(FEV1)% of forced vital capacity among the four groups
(* group A, control; * group B, patients with asthma;
~ group C, non- or ex-smoking patients with COPD; &
group D, currently smoking patients with COPD).
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oxidative stress could possibly attribute to the pathophy-
siology of asthma and COPD in leading to airflow
obstruction. These results are in agreement with the
previous reports that showed an increased oxidative stress
in the airways by measuring exhaled hydrogen peroxide
(H2O2) in patients with adult respiratory distress syndrome
(ARDS), asthma and COPD (4–6), and the plasma level of
lipid peroxides in patients with asthma, COPD and smokers
(7). However, we could not observe the further increases in
the level of lipid peroxides in currently smoking patients
with COPD compared to that of non- or ex-smoking
patients with COPD. Further investigation of whether
smoking could aect the level of lipid peroxides and airflow
obstruction would also be necessary in asthmatics.FIG. 4. The correlation between the plasma level of lipid
peroxides and the serum level of theophylline in patients
with asthma.Oxidized fatty acids, including lipid peroxides, exert their
biological activities as an endogenous calcium ionophore
(17). Calcium ionophore has been shown to induce
bronchial hyperresponsiveness in guinea-pigs (18), and an
increased plasma level of lipid peroxides is observed in a
guinea-pig model of endotoxin-induced airway inflamma-
tion accompanied by bronchial hyperresponsiveness (19).
On the basis of these observations, the present study
suggests that an increase in pulmonary oxidative stress may
be involved partly in the pathophysiological conditions of
asthma.
The present study also demonstrated a weak but
significant negative correlation between the blood levels
of lipid peroxides and theophylline in asthmatics, but
curiously not in COPD. Because there is an evidence to
suggest that PDE activity is elevated in leukocytes from
patients with asthma (20), the diverse responsiveness
clinically to theophylline and relations of the blood levels
of lipid peroxides and theophylline among patients with
asthma and COPD could be at least partly explained. It is
dicult, however, to indicate that theophylline has an
inhibitory eect on oxidative stress only with the present
data.
As shown in patients with asthma and COPD (21–23), an
increased oxidant burden is thought to result from the
release of reactive oxygen intermediates from circulating or
airspace leukocytes. While there are several reports
concerning inhibitory eects of theophylline on the
respiratory burst in neutrophils, eosinophils, and macro-
phages (24), further examination of the dierences in PDE
activities in leukocytes and in the airway tissues is needed.
Although in vitro studies have shown that steroids reduce
the generation of reactive oxygen species by neutrophils
(25) and stimulate the synthesis of glutathione, an
antioxidant, in liver (26), the present study showed that
there were no significant dierences in the plasma levels of
lipid peroxides among subjects treated with or without
steroids in patients with asthma or COPD, probably
because of short numbers of subjects and the relatively
low doses of steroids administered by inhalation and/or
orally. Treatment with steroids, however, are reported not
to appear to alter the level of exhaled hydrogen peroxide or
plasma lipid peroxides in patients with asthma or COPD
(5–7). Beneficial eects of long-term corticosteroids on lung
function in patients with chronic airflow obstruction remain
to be seen.
In conclusion, the present results suggest at least that
there may be an increased oxidative stress involved in
asthma and COPD. And those indicate that oxidative stress
could possibly attribute to the pathophysiology leading to
airflow obstruction in asthma and COPD and that
theophylline could potentially inhibit oxidative stress in
the process of airway inflammation involved in asthmatics.
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